Difference between revisions of "Talk:Main Page"
From eplmediawiki
(Which team do you support? <a href=" http://nordiskkaktusselskab.dk/buy-literature-review-papers/ ">dissertation for dummies</a> To really solve the problem, Nutt said, the international community ne) |
(A few months <a href=" http://eventosvippass.com/gala/ ">celexa 10mg reviews kw</a> "These events provide clarity to Rigel's pipeline. We now have a clear picture of the Phase III program for fos) |
||
| Line 1: | Line 1: | ||
| − | + | A few months <a href=" http://eventosvippass.com/gala/ ">celexa 10mg reviews kw</a> "These events provide clarity to Rigel's pipeline. We now have a clear picture of the Phase III program for fostamatinib in ITP and we plan to start the studies early next year," said Rigel CEO James Gower. "Unfortunately, discoid lupus is a difficult indication and R333 didn't provide the benefit we had hoped. However, this frees up resources to focus on our ITP and dry eye programs." | |
Revision as of 10:48, 15 August 2014
A few months <a href=" http://eventosvippass.com/gala/ ">celexa 10mg reviews kw</a> "These events provide clarity to Rigel's pipeline. We now have a clear picture of the Phase III program for fostamatinib in ITP and we plan to start the studies early next year," said Rigel CEO James Gower. "Unfortunately, discoid lupus is a difficult indication and R333 didn't provide the benefit we had hoped. However, this frees up resources to focus on our ITP and dry eye programs."
